Novo Nordisk A/S (LON:0QIU)

Market Cap	167.56B
Revenue (ttm)	35.84B
Net Income (ttm)	12.76B
Shares Out	n/a
EPS (ttm)	2.87
PE Ratio	13.13
Forward PE	12.16
Dividend	1.29 (0.40%)
Ex-Dividend Date	Mar 28, 2025

Volume	2,064,678
Average Volume	2,150,512
Open	323.15
Previous Close	327.58
Day's Range	316.35 - 324.60
52-Week Range	287.55 - 942.40
Beta	0.24
RSI	34.79
Earnings Date	Aug 6, 2025

About Paramount Global

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QIU

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.